Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin

Enfortumab vedotin is an antibody-drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacri-mation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedo-tin. Enfortumab vedotin is not previously known to cause cataract development or progres-sion and, thus, our patient's presentation may reflect the first report of an undocumented adverse effect of this novel agent.

Automated summary

Enfortumab vedotin, an antibody-drug conjugate recently approved by the FDA for the treatment of urothelial cancer, was associated with the development of bilateral anterior subcapsular cataracts in a reported case. This adverse effect of cataract development had not been previously documented with the use of Enfortumab vedotin.